| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
AES-135 prevents cancer cells from proliferating. BT189, D425, D458, MV4, BT143, and 1.4 µM, 0.27 µM, 0.94 µM, 1.9 µM, 2.72 µM, 2.1 µM, 15.0 µM, 1.6 µM, and 19.2 µM are the IC50 values of these compounds. These cells are called MRC-9, -11, PC-3, MDA-MB-231, MOLM-13, and K562 [1].
|
|---|---|
| ln Vivo |
AES-135 (50 mg/kg; intraperitoneal injection; 5 days per week; for 1 month) treatment significantly enhanced the survival rate of C57Bl/6 mice implanted with KPC2 cells [1]. NSG mice were dosed with a single intraperitoneal (IP) injection of 20 mg/kg, and blood was taken after 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours. AES-135 achieves μM concentrations in blood, achieving a Cmax of 7452 ng/mL (10.74 μM) after 30 minutes and remaining for 8 hours. Blood concentrations of AES-135 were dose-dependent, reaching an average of 323 ng/mL (0.47 μM) at a dose of 10 mg/kg and an average of 1829 ng/mL (2.64 μM) at a dose of 40 mg/kg. AES-135 demonstrates remarkable pharmacokinetic properties in mice, having an in vivo half-life of 5.0 hours [1].
|
| Animal Protocol |
Animal/Disease Models: C57Bl/6 mice injected with KPC2 cells [1]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; 5 days a week; lasted for 1 month. Experimental Results: The survival rate of mice was Dramatically increased. |
| References |
| Molecular Formula |
C33H29F6N3O5S
|
|---|---|
| Molecular Weight |
693.655888319016
|
| Exact Mass |
693.173
|
| CAS # |
2361659-61-0
|
| PubChem CID |
137628685
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
48
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC(=CC=1)F)(N(CC1C(=C(C(=C(C=1F)F)F)F)F)CC(N(C1C=CC(C(NO)=O)=CC=1)CC1C=CC(=CC=1)C(C)(C)C)=O)(=O)=O
|
| InChi Key |
LTRKEOBJRDKIHB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H29F6N3O5S/c1-33(2,3)21-8-4-19(5-9-21)16-42(23-12-6-20(7-13-23)32(44)40-45)26(43)18-41(48(46,47)24-14-10-22(34)11-15-24)17-25-27(35)29(37)31(39)30(38)28(25)36/h4-15,45H,16-18H2,1-3H3,(H,40,44)
|
| Chemical Name |
4-[(4-tert-butylphenyl)methyl-[2-[(4-fluorophenyl)sulfonyl-[(2,3,4,5,6-pentafluorophenyl)methyl]amino]acetyl]amino]-N-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~144.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4416 mL | 7.2081 mL | 14.4163 mL | |
| 5 mM | 0.2883 mL | 1.4416 mL | 2.8833 mL | |
| 10 mM | 0.1442 mL | 0.7208 mL | 1.4416 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
